Pay in 4 interest-free payments of $5.52 Learn more
Ships within 48 hours · Estimated delivery Aug 25 - Aug 30
Participants were randomized to dulaglutide at 1.5 or 0.75 mg or to metformin at 1,000 mg twice daily.
A Phase I clinical trial is anticipated to start in Q3 2025
Weight loss typically continues, with clinical trials showing that semaglutide 2.4 mg (Wegovy) produces average weight loss of approximately 15% by week 68, while tirzepatide (Zepbound) has demonstrated weight loss of approximately 15-21% across different doses by week 72
It works by inhibiting the NNMT enzymea known contributor to fat storage and metabolic slowdown
The amount of weight lost was the same for the participants taking GLP-1s or other weight loss drugs
US$ 29.57
US$ 28.05
US$ 26.41
